Comparative Pharmacology
Head-to-head clinical analysis: AVOPEF versus LONSURF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVOPEF versus LONSURF.
AVOPEF vs LONSURF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avopef is a synthetic peptide analog that acts as a selective antagonist of the nociceptin/orphanin FQ (N/OFQ) receptor (NOP), modulating pain pathways and stress responses. It also exhibits partial agonist activity at mu-opioid receptors, contributing to its analgesic and anxiolytic effects.
LONSURF (trifluridine and tipiracil) is a combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil. Trifluridine incorporates into DNA and inhibits cell proliferation, while tipiracil increases trifluridine exposure by inhibiting its degradation by thymidine phosphorylase.
Adults: 400 mg intravenously every 8 hours for 7-14 days.
Adults: 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is 2.0-3.5 hours; prolonged to 6-12 hours in renal impairment.
Trifluridine: terminal half-life approximately 1.4-2.1 hours; tipiracil: terminal half-life approximately 2-3 hours. Clinical context: short half-lives necessitate twice-daily dosing on Days 1-5 and 8-12 of a 28-day cycle.
Renal: 70-80% unchanged; Biliary/Fecal: 15-20%; minor hepatic metabolism.
Primarily renal: tipiracil is excreted unchanged in urine (approximately 50% of dose); trifluridine is eliminated via metabolism and renal excretion (as metabolites and unchanged drug). Fecal elimination accounts for <3% of total clearance.
Category C
Category C
Antineoplastic
Antineoplastic